Investor Relations

Press Releases

  • DATE
  • TITLE AND SUMMARY
  • VIEW
June 14, 2017

Update on Long term Survival of VB-111 Treated Patients to be Presented at BIO on June 20 TEL AVIV, Israel , June 14, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT) today announced Prof. Dror Harats , CEO,  will provide a corporate overview at the 2017 BIO International Convention in San...

June 08, 2017

TEL AVIV, Israel , June 08, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT) today announced that it has been awarded a grant of 8.75 million New Israeli Shekels (approximately $2.5 million ) by the Israel Innovation Authority .  The grant will support clinical trials and development...

June 05, 2017

TEL AVIV, Israel , June 05, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), today announced the presentation of new data demonstrating that treatment with VB-111 (ofranergene obadenovec) induced durable tumor regression and attenuation of tumor growth in patients with recurrent...

May 15, 2017

TEL AVIV, Israel , May 15, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, announced financial results for the first quarter ended March 31, 2017 , as...

May 11, 2017

TEL AVIV, Israel , May 11, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT) today announced new preclinical data indicating that treatment with ofranergene obadenovec (VB-111) augments the anti-tumor activity of a PD-L1 blocker in lung cancer and melanoma models....

View all press releases »